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Abstract
Aims
This study documented the treatment cascade for engagement in care and abstinence at
treatment exit as well as examined correlates of these outcomes for the first certified Matrix
Model1 substance abuse treatment site in Sub-Saharan Africa.
Design
This retrospective chart review conducted at a resource-limited community clinic in Cape
Town, South Africa, assessed treatment readiness and substance use severity at treatment
entry as correlates of the number of sessions attended and biologically confirmed absti-
nence at treatment exit among 986 clients who initiated treatment from 2009–2014. Socio-
demographic and clinical correlates of treatment outcomes were examined using logistic
regression, modeling treatment completion and abstinence at treatment exit separately.
Results
Of the 2,233 clients who completed screening, approximately 44% (n = 986) initiated treat-
ment. Among those who initiated treatment, 45% completed at least four group sessions,
30% completed early recovery skills training (i.e., at least eight group sessions), and 13%
completed the full 16-week program. Approximately half (54%) of clients who provided a
urine sample had negative urine toxicology results for any substance at treatment exit.
Higher motivation at treatment entry was independently associated with greater odds of
treatment completion and negative urine toxicology results at treatment exit.
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Conclusions
Findings provide initial support for the successful implementation the Matrix Model in a
resource-limited setting. Motivational enhancement interventions could support treatment
initiation, promote sustained engagement in treatment, and achieve better treatment
outcomes.
Introduction
Historically there has been a gap between research and implementation of substance abuse
treatment in developed countries [1, 2]. This gap is further heightened in low-and-middle-
income countries (LMICs) such as South Africa (SA), where there is limited access to empiri-
cally-supported treatments and a shortage of trained health workers to deliver evidence-based
interventions [3, 4]. In such settings where resources are scarce and the need for treatment is
large, it is critical to understand the implementation of evidence-based treatments to ensure cli-
ents are receiving effective and acceptable care [5].
SA’s Western Cape province has pushed towards implementing evidence-based approaches
to substance abuse treatment because of the well-characterized methamphetamine or “tik” epi-
demic in this region. Since 2002, Cape Town has experienced a 150-fold increase in methamphet-
amine users presenting for substance abuse treatment [6]. Because this region is thought to be
among those with the highest prevalence of methamphetamine addiction globally [6], research is
needed to document the implementation of evidence-based substance abuse treatment.
In 2007, in response to the drastic increase in methamphetamine use in this region, the City
of Cape Town developed a multi-sectorial alcohol and drug strategy to manage the rapidly
growing drug and alcohol-related challenges. One of the objectives of this strategy was to
improve access to evidence-based treatment services through providing the Matrix Model of
outpatient treatment for stimulant use disorders [7] within primary health care in local peri-
urban communities. Developed and extensively tested in the United States (US), the Matrix
model is an evidence-based, 16-week outpatient cognitive-behavioral treatment that includes
individual, group, and family sessions [8–10].
Few published reports have documented the implementation of the Matrix Model in LMICs.
Thus, it is unclear whether evidence of the effectiveness of this model for US populations can be
extended to countries such as SA, where structural factors (e.g., poverty, shortages of trained
health care workers, inability to take extended leave from work, and long distances to care) are
substantial barriers to engagement in substance abuse treatment [11]. The overarching goal of
this study is to describe one of the first examples of Matrix Model implementation in one low-
income, resource-limited community clinic in Cape Town. The primary objectives were to: 1)
document the services provided and characteristics of the treatment-seeking population; 2)
describe the “cascade” of treatment engagement from screening through completion; 3) examine
abstinence at treatment exit using urinalysis results; and 4) explore sociodemographic and clini-
cal correlates of treatment engagement and abstinence at treatment exit.
Method
2.1. Setting
This study took place at the first certified Matrix Model site in Africa. The site is based within a
community health center in a peri-urban area outside Cape Town. The substance abuse
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treatment program was launched in 2008, and in 2010 it was certified as a Matrix Model1 ‘pro-
gram of excellence’ [12]. The clinic serves a low-income, largely “coloured” (an apartheid clas-
sification for ‘mixed race’ that is still in use) community in the surrounding area; however,
clients are not limited to this catchment area due to the lack of substance abuse treatment ser-
vices in the region. Although the program primarily serves methamphetamine users, many cli-
ents use multiple substances including alcohol, heroin, methaqualone (mandrax), and
cannabis.
2.2. Description of Matrix program
This outpatient treatment program is based on the standardized Matrix Model1 [7]. The core
16-week program consists of 8 sessions of early recovery (with two early recovery groups per
week for the first four weeks), 32 sessions of relapse prevention (two relapse prevention groups
per week for sixteen weeks), and other optional weekly individual or conjoint sessions. Clients
typically attend two to four sessions per week. At least one mandatory random urine drug
panel test screen is required on a weekly basis from all clients; for clients who are primary alco-
hol users, an alcohol breathalyzer test is required.
The first point of contact is by a non-appointment screening visit conducted by a lay coun-
selor. Starting in November 2011, the World Health Organization Alcohol, Smoking, and Sub-
stance Involvement Screening Test (ASSIST) [13], the Stages of Change Readiness and
Treatment Eagerness Scale (SOCRATES) [14] and a urine drug test with alcohol breathalyzer
were administered at the screening visit. Referrals to other services are made for clients
experiencing severe withdrawals from alcohol, heroin users with difficulties remaining absti-
nent on an outpatient basis (referred for detoxification services and residential treatment),
those experiencing psychosis, where there is serious suicide risk (referred to a psychiatric hos-
pital), or those unable to attend an intensive outpatient program (e.g., for work reasons). If the
client is suitable for the Matrix Model program, the first session (third contact) is generally
attended within two days of enrollment.
2.2.1. Matrix site therapists. The lay counselor is trained in basic substance abuse and
mental health counseling skills. The minimum educational requirement for a therapist is a
four-year degree in social work or counseling psychology; and for the Key Supervisor, a Mas-
ters level degree in a related field. Therapists receive Matrix Core Training from US-based
Matrix program trainers and complete a 5-day Motivational Interviewing Network of Trainers
(MINT)-certified Motivational Interviewing course. The program Key Supervisor, experienced
in implementation of the Matrix Model, provides individual case supervision and Matrix
supervision sessions once per month.
2.3. Procedures
2.3.1. Data extraction. We retrospectively evaluated services provided at this clinic from
one-year post inception (June 2009) until May 2014. The cut off point for inclusion in the eval-
uation was 4 months prior to the start of data extraction so that all included participants had
the opportunity to complete the 16-week program. Informed consent was waived on the basis
of it being a retrospective chart review and de-identification of data. Data used in this research
project were extracted from chart reviews conducted on all existing intake and discharge
assessments collected during routine care. All data identifying clients were removed from clini-
cal records before research activities were implemented. The chart-review was approved by the
University of Cape Town Human Research Ethics Committee and City of Cape Town Health
Department.
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2.3.2. Measures. Sociodemographics and treatment history: Age, ethnicity, gender, educa-
tion level, relationship status, and employment, and number of previous treatment episodes
were assessed.
ASSIST V.3.0 [13]: The ASSIST assesses level of substance use severity for alcohol, tobacco
and illicit drugs. A total score is calculated for each substance that indicates level of substance
use involvement, which is then used to categorize the person into low (0–3), medium (4–26)
and high risk (>27) of substance-related health problems for illicit drugs, and low (0–10),
medium (11–26) and high risk (>27) for alcohol.
SOCRATES [14]: The SOCRATES assesses readiness for change among alcohol and sub-
stance users, and has been found to have good internal consistency and reliability across
diverse samples. It yields three composite scores ranging from 10 (very low) to 90 (very high):
Recognition indexes acknowledgment of substance use related problems (α = .85–95). Ambiva-
lencemeasures degree of uncertainty about changing substance use (α = .60–.88). Taking Steps
provides information regarding the degree to which individuals are taking concrete actions
towards changing substance use (α = .83–.96) [14].
Clinical outcome variables: Treatment initiation and engagement. Treatment initiation was
defined as attending at least one group or individual session. To define treatment engagement,
clinically meaningful cut-offs were based on the existing evidence-based Matrix Model pro-
gram structure in accordance with the City’s Matrix Key Supervisor (WB): 1) attending at least
four group sessions (2 weeks), 2) attending at least eight group sessions (i.e., completing early
recovery; one month); 3) attending at least sixteen group sessions (2 months); 4) attending at
least 24 groups sessions (three months); and 5) completion of the full 16-week program (i.e.,
completing relapse prevention; 4 months).
Urine tox screen results at treatment exit. Urine drug tests were administered on a weekly
basis for all clients using a Drugs of Abuse Panel Test Card for amphetamine, benzodiazipine,
cocaine, opiate, marijuana (THC). Tox screen results at treatment exit were assessed using
urine drug test results (positive or negative) for all substances in the last two weeks of each cli-
ent’s clinic attendance; any use in the last two weeks was defined as a positive screen, and no
use was defined as a negative screen.
2.3.3. Statistical analysis. To describe the cascade of substance abuse treatment engage-
ment, the number of group sessions attended was calculated to document the markers of treat-
ment engagement described above. Next, frequencies of urine tox screen results were
calculated during the two weeks before each client exited treatment. Finally, sociodemographic
and clinical correlates of treatment outcomes were examined using logistic regression, model-
ing treatment completion and abstinence at treatment exit separately.
Results
3.1. Descriptive characteristics of sample
From June 2009 through May 2014 a total of 2,233 clients had a screening visit at the Matrix
Model1 program. Clients were 66% male (n = 1,471), 97% “coloured” (n = 2,161), 86% unem-
ployed (n = 1,912), 68% single (n = 1,507), and mean age of 28.3 (SD = 7.6) years. Metham-
phetamine (61%; n = 1,329) and heroin (24%; n = 534) were the two most commonly reported
primary substances of abuse. For 76% (n = 1,704) of the sample, this was the first reported sub-
stance abuse treatment episode. Of those who received the ASSIST (n = 1,041), 76% were in the
moderate- to high-risk categories for amphetamines (n = 790) and 28% in the moderate- to
high-risk categories for opioids (n = 288). More than half (58%) of clients were in the moderate
to high-risk categories for more than one substance.
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3.2. Cascade of treatment engagement
Fig 1 illustrates engagement in outpatient Matrix Model1 substance abuse treatment among
clients who initiated treatment. Of the 2,233 clients who completed screening, 44% (n = 986)
initiated treatment. Among those who initiated treatment, less than half (45%; n = 448) com-
pleted two weeks of the program, approximately one-third (n = 293) completed 1 month of
treatment, which marks completion of the early recovery module, and one out of eight (13%;
n = 129) completed the full program, which marks the completion of relapse prevention.
3.3. Urine toxicology screening results
Of the 986 clients who initiated treatment, 564 (57%) had a urine tox screen result at treatment
exit, which could have occurred at any time during the 16-week program. Of those, 304 (54%)
had a negative result at treatment exit for all substances. Of those who completed at least eight
group sessions (first month of treatment) and had urine tox screen results available in their last
two weeks of treatment (n = 260), 69% had a negative result at treatment exit for all substances
(n = 180).
3.4. Multivariable models
As shown in Table 1, only treatment motivation as measured by the SOCRATES was signifi-
cantly associated with treatment completion. Higher scores on the “Taking Steps” and “Recog-
nition” subscales as well as lower scores on the “Ambivalence” subscale were independently
associated with greater odds of treatment completion. As shown in Table 2 higher scores on
the “Taking Steps” subscale were independently associated with greater odds of abstinence at
treatment exit, and greater severity of methamphetamine use was independently associated
with lower odds of abstinence at treatment exit.
Discussion
Findings provide one of the first opportunities to describe implementation of the evidence-
based Matrix Model cognitive-behavioral substance abuse treatment program in a resource-
limited setting in SA. To our knowledge, there have been limited examples, if any, of studies
that have documented the implementation of evidence-based substance abuse treatment in a
Fig 1. Cascade of engagement in care (N = 986). Attending 8 groups sessions = completion of early
recovery; Complete full 16 week program = completion of relapse prevention.
doi:10.1371/journal.pone.0147900.g001
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resource-limited setting in Sub-Saharan Africa, where many structural barriers to treatment
exist and there are limited options for evidence-based care [15, 16]. This Matrix site provides
treatment in an area of SA with high rates of polysubstance use and one of the highest rates of
methamphetamine use in the world [10].
Table 1. Correlates of treatment completion (N = 129).
B S.E. Wald df Sig. Exp 95% C.I.
Lower Upper
Sex .27 .43 .40 1 .52 1.31 .56 3.06
Employment .80 .75 1.12 1 .29 2.23 .50 9.8
Age .03 .02 1.86 1 .17 1.03 .98 1.08
Socrates
Recognition .12 .06 3.96 1 .04 1.13 1.0 1.28
Ambivalence -.14 .06 4.74 1 .02 .86 .76 .98
Taking Steps .12 .04 7.00 1 .00 1.12 1.03 1.23
Previous Treatment Episode -.08 .44 .04 1 .84 .91 .38 2.18
ASSIST
Methamphetamine -.00 .01 .00 1 .95 .99 .96 1.0
Marijuana -.01 .01 .64 1 .42 .98 .95 1.02
Alcohol -.01 .02 .18 1 .66 .98 .93 1.04
Opioids -.03 .02 3.01 1 .08 .96 .92 1.00
Constant -5.36 1.18 20.53 1 .00 .00
Note: Dependent variable (treatment completion) was coded as 0 = less than 16 weeks
1 = greater than 16 weeks.
ASSIST and SOCRATES scores were mean centered for ease of interpretation.
doi:10.1371/journal.pone.0147900.t001
Table 2. Correlates of a negative urine toxicology result in last two weeks of treatment (N = 304).
B S.E. Wald df Sig. Exp 95% C.I.
Lower Upper
Sex .37 .30 1.52 1 .21 1.45 .80 2.65
Employment .29 .41 .48 1 .48 1.34 .58 3.04
Age .01 .02 .48 1 .48 1.01 .97 1.05
Socrates
Recognition .03 .03 .87 1 .35 1.03 .96 1.10
Ambivalence -.06 .05 1.49 1 .22 .93 .84 1.04
Taking Steps .10 .02 12.63 1 .00 1.10 1.04 1.16
Previous Treatment Episode -.44 .31 2.04 1 .15 .64 .34 1.17
ASSIST
Methamphetamine -.02 .01 5.24 1 .02 .97 .95 .99
Marijuana -.01 .01 1.37 1 .24 .98 .96 1.00
Alcohol .03 .01 3.83 1 .05 1.03 1.00 1.07
Opioids -.00 .01 .21 1 .64 .99 .96 1.02
Constant -.87 .76 1.32 1 .24 .41
Note: Dependent variable (drug test result in last 2 weeks of treatment) was coded as 0 = positive, 1 = negative.
ASSIST and SOCRATES scores were mean centered for ease of interpretation.
doi:10.1371/journal.pone.0147900.t002
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Over a period of 72 months, the clinic had attrition rates comparable to that of published
research conducted in industrialized nations. For example, the attrition rate at the Matrix
Model clinic site between the initial request for service at screening and treatment initiation
was 56%, which is consistent with rates between 29%–63% reported in the literature [2]. Simi-
larly retention after 30 days of treatment was 30%, consistent with rates of 34% reported in the
literature for patients with no prior treatment [2, 17]. Overall, findings highlight that enhanc-
ing initiation and engagement in treatment is an important area for further study to optimize
the benefits of substance abuse treatments in LMICs and industrialized nations.
The opportunity for a drop-in screening visit at this site increases rates of initial contact
with the site (versus starting with a visit that requires an appointment), which in turn may also
inflate the rate of dropout seen here from screening to the first treatment session. That being
said, the population this Matrix site serves (and other populations in resource limited settings)
face substantial challenges around treatment initiation and retention including: gaining
employment, the impact of gang related activities in the clinic neighborhood, lack of child-care
facilities, migration, transport related issues [18], and few other evidence-based substance
abuse treatment referral options [19]. The influence that these factors have on treatment reten-
tion and possible solutions to overcome these structural barriers should be addressed in future
clinical research in LMICs and industrialized nations.
It should also be noted here that early termination of treatment does not equate to treatment
failure. Clients may have terminated treatment for reasons other than relapse, including find-
ing employment. Further, the rate of negative drug tox screens for all clients who were tested
two weeks prior to treatment termination (54%) and those who completed at least one month
of treatment (69%) suggest that even limited interaction with the Matrix Model program may
assist clients with achieving some degree of abstinence. The association of degree of engage-
ment with treatment outcomes should be examined in future research.
Motivation emerged as a key psychological factor that predicted greater engagement in
treatment and better treatment outcomes. Those who reported awareness of substance-related
problems (i.e., Recognition) and taking concrete steps to reduce substance use (i.e., Taking
Steps) at treatment entry had greater odds of completing the full 16-week substance abuse
treatment program. Greater uncertainty about setting goals for changing one’s relationship
with substances (i.e., Ambivalence) was independently associated with decreased odds of treat-
ment completion. Findings point to the need for expanded efforts to enhance motivation for
treatment, including approaches like contingency management that provide motivational
incentives as positive reinforcement for abstinence that could also mitigate the effect of struc-
tural barriers to remaining engaged in treatment in this resource-limited setting [20–23].
Limitations
The study findings must be interpreted in the context of important limitations, including those
inherent in this being a retrospective chart review. Urine drug screen data was available only
for the last two weeks of program attendance, and as such we were unable to document the
number of clients at each step in the cascade with negative urine drug test results. Additionally,
we could not assess reasons for ‘drop-out’ and were limited to only examining the measures
included in routine clinical assessments. Tobacco use is not treated explicitly in this clinic set-
ting and was therefore not included in our analysis. Alcohol users had greater odds of absti-
nence at treatment exit, but this may be due to the fact that breathalyzer data were not
extracted. Further research is needed to examine the extent to which those who do not have
stimulant use disorders achieve comparable benefits from the Matrix Model in this setting.
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Conclusions
Findings provide initial support for the successful implementation the Matrix Model in a
resource-limited setting. We found that clients with heterogeneous, severe substance use pro-
files were making contact with the program for their first treatment episode. Rates of initiation
and engagement were comparable to the implementation of substance abuse treatment in
industrialized nations. Motivational enhancement interventions could support treatment initi-
ation, promote sustained engagement in treatment, and achieve better treatment outcomes.
Future mixed methods research should examine whether the barriers faced to retention in care
are distinct in this setting.
We hope this work spurs further efforts to address the many remaining empirical questions
about how to optimally deliver evidence-based substance abuse treatment in resource-limited
settings where huge clinical needs exist, particularly related to questions regarding how to
enhance motivation and address structural barriers to remaining engaged in care.
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